Clinical trials are an important part of medical research designed to better understand a disease and how new medicines may help health conditions.
Baskings Australia plans to initiate the clinical program of DTRI-031, its lead compound, by conducting a phase 1 clinical study in Q3 2021 at a phase 1 facility co-located with the Alfred Hospital in Melbourne. This clinical study is designed to enroll up to 40 study participants, aged 18-50 years old, in 5 dose cohorts. The goal of the study is to assess the safety, tolerability, pharmacokinetics and biological activity of DTRI-031. The phase 1 study will be followed by a clinical study in patients who have had an acute ischemic stroke.